These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 10456926)
1. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926 [TBL] [Abstract][Full Text] [Related]
2. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889 [TBL] [Abstract][Full Text] [Related]
3. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis. De Rose V; Arduino C; Cappello N; Piana R; Salmin P; Bardessono M; Goia M; Padoan R; Bignamini E; Costantini D; Pizzamiglio G; Bennato V; Colombo C; Giunta A; Piazza A Eur J Hum Genet; 2005 Jan; 13(1):96-101. PubMed ID: 15367919 [TBL] [Abstract][Full Text] [Related]
4. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease. Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165 [TBL] [Abstract][Full Text] [Related]
5. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
6. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. van Heeckeren AM; Schluchter MD; Drumm ML; Davis PB Am J Physiol Lung Cell Mol Physiol; 2004 Nov; 287(5):L944-52. PubMed ID: 15246977 [TBL] [Abstract][Full Text] [Related]
7. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Levy H; Kalish LA; Cannon CL; García KC; Gerard C; Goldmann D; Pier GB; Weiss ST; Colin AA Pediatr Pulmonol; 2008 May; 43(5):463-71. PubMed ID: 18361452 [TBL] [Abstract][Full Text] [Related]
8. Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry. Vongthilath R; Richaud Thiriez B; Dehillotte C; Lemonnier L; Guillien A; Degano B; Dalphin ML; Dalphin JC; Plésiat P PLoS One; 2019; 14(1):e0210201. PubMed ID: 30620748 [TBL] [Abstract][Full Text] [Related]
9. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Steinkamp G; Wiedemann B Thorax; 2002 Jul; 57(7):596-601. PubMed ID: 12096202 [TBL] [Abstract][Full Text] [Related]
10. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
11. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Pier GB Proc Natl Acad Sci U S A; 2000 Aug; 97(16):8822-8. PubMed ID: 10922041 [TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients. Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. Li Z; Kosorok MR; Farrell PM; Laxova A; West SE; Green CG; Collins J; Rock MJ; Splaingard ML JAMA; 2005 Feb; 293(5):581-8. PubMed ID: 15687313 [TBL] [Abstract][Full Text] [Related]
14. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. Schroeder TH; Reiniger N; Meluleni G; Grout M; Coleman FT; Pier GB J Immunol; 2001 Jun; 166(12):7410-8. PubMed ID: 11390493 [TBL] [Abstract][Full Text] [Related]